Soteria Biotherapeutics

soteria is developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors. soteria’s highly innovative t-lite™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing. t-lites incorporate a small molecule-controlled switch into a conventional bispecific t-cell engaging antibody which enables precise on/off control over the timing and magnitude of redirected t-cell cytotoxic activity. soteria was founded in 2018 with technology licensed from uc san francisco and is based in san francisco, california.